Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-4208, HS-10382
TERN-701 · 1 trial · 1 indication
Urine will be collected to determine the Aeurine,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.
Urine will be collected to determine the Aeurine,14C of radiolabeled \[14C\]-TERN-701.
Feces will be collected to determine the Aefeces,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.
Feces will be collected to determine the Aefeces,14C of radiolabeled \[14C\]-TERN-701.
Urine and Feces will be collected to determine the Aetotal,14C,t1-t2 of radiolabeled \[14C\]-TERN-701.
Urine and Feces will be collected to determine the Aetotal,14C of radiolabeled \[14C\]-TERN-701. Calculated as, Aetotal,14C= Aeurine,14C +Aefeces,14C.
Blood samples will be collected to determine the Cmax of TERN-701.
Blood samples will be collected to determine the Tmax of TERN-701.
Blood samples will be collected to determine the t1/2 of TERN-701.
Blood samples will be collected to determine the AUC0-Last of TERN-701.
Blood samples will be collected to determine the AUC0-inf of TERN-701.
Blood samples will be collected to determine the CL/F of TERN-701.
Blood samples will be collected to determine the Vz/F of TERN-701.
Blood samples will be collected to determine the Total \[14C\]-Radiolabel, calculated as the AUCinf of non-radiolabeled TERN-701 in plasma divided by the AUCinf of total \[14C\]-radiolabel in plasma.
Blood samples will be collected to determine the Tmax of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the t1/2 of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the AUC0-last of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the AUC0-Inf of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the Cmax of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the Tmax of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the t1/2 of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the AUC0-last of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the AUC0-Inf of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the Cmax of radiolabeled \[14C\]-TERN-701.
Urine samples will be collected to determine the Aeurine of radiolabeled \[14C\]-TERN-701.
Urine samples will be collected to determine the CLr of radiolabeled \[14C\]-TERN-701.
Urine samples will be collected to determine the %Feurine of radiolabeled \[14C\]-TERN-701.
Feces samples will be collected to determine the Aefeces of radiolabeled \[14C\]-TERN-701.
Feces samples will be collected to determine the %Fefeces of radiolabeled \[14C\]-TERN-701.
Blood samples will be collected to determine the Percentage of AUC of \[14C\]-radiolabel TERN-701 metabolite in plasma.
Feces samples will be collected to determine the percentage of administered dose of \[14C\]-radiolabel TERN-701 metabolite in feces.
Urine samples will be collected to determine the percentage of \[14C\]-radiolabel TERN-701 metabolite in urine.
| Arm | Type | Description |
|---|---|---|
| [14C]-TERN-701 | EXPERIMENTAL | Participants receive a single oral dose of radiolabeled TERN-701 (\[14C\]-TERN-701) on Day 1. |
| Name | Type | Description |
|---|---|---|
| TERN-701 | DRUG | Oral Liquid radiolabeled with \[14C\]-TERN-701 |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has body mass index (BMI) ≥18.5 and ≤32.0 kg/m\^2 * Is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history or presence of any me...
TERN-701 is an investigational small molecule developed by Merck & Company, Inc. (ticker MRK). It has been studied in a Phase 1 clinical trial in healthy adult male participants. Its therapeutic indications have not been disclosed.
TERN-701 is developed by Merck & Company, Inc., which trades under the ticker MRK. The Phase 1 trial of the compound was registered under the code MK-4208-002/TERN701-1016, linking the TERN-701 designation with Merck's MK-4208 numbering.
TERN-701 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and is not described as approved for any indication.
TERN-701 has been evaluated in one completed Phase 1 trial, NCT07839000, titled a clinical trial to evaluate [14C]-MK-4208/[14C]-TERN-701 in healthy adult male participants. The trial enrolled 8 healthy male volunteers aged 18 years and older in the United States and was uncontrolled.
The completed Phase 1 trial, NCT07839000, was an uncontrolled study with no randomization and no blinding. It enrolled 8 healthy adult male participants aged 18 years and older at sites in the United States, and it was not biomarker selected.